Skip to content

Cognitive Behavioral Treatment to Reduce Alcohol Use Among HIV-Infected Kenyans

Alcohol & HIV in Kenya: Stage 1 Trial of a Peer-Led Alcohol Behavior Intervention

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00792519
Acronym
KHBS
Enrollment
75
Registered
2008-11-18
Start date
2009-02-28
Completion date
2010-12-31
Last updated
2011-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcohol Abuse, Alcohol Dependence, Binge Drinking, HIV Infections

Keywords

alcohol use, HIV, cognitive behavioral treatment, Kenya, hazardous/binge drinking, alcohol abuse/dependence

Brief summary

This study will determine whether a cognitive behavioral intervention that demonstrates strong evidence in the U.S. of reducing alcohol use is effective when delivered by paraprofessionals in Kenya and compared against a usual care support group.

Detailed description

Alcohol use and abuse have been associated with increased risky sexual behavior, poor adherence to antiretroviral therapy (ARVs) and toxicity from ARVs among those with HIV infection. As such, alcohol use and abuse have a major impact on HIV transmission and disease progression. Because alcohol abuse is widespread in Kenya, with estimates of hazardous drinking as high as 68% in general medicine clinics and 53% in HIV clinics, this Stage 1 pilot project will develop and evaluate a paraprofessionally led group cognitive behavioral treatment (CBT) targeting alcohol use among HIV infected Kenyans who were initiated on ARV therapy in the past year. Although CBT is well-suited to the Kenyan setting because it is comparatively structured and consistent with the Kenyan conceptual model of drinking behavior, it requires adaptation for group paraprofessional delivery due to the extremely limited supply of Kenyan mental health professionals. The goal of this 24-month capacity-building R21 study is to evaluate the efficacy of a novel application of CBT, a 6-session paraprofessionally led group in Eldoret, Kenya, when compared against a usual care support group, to reduce hazardous and binge drinking among adult persons infected with HIV. This work will be conducted via the Kenya-U.S. HIV and Alcohol Research and Prevention Partnership-an experienced team of Kenyan and U.S. physicians, behavioral scientists, recovered substance users and persons infected with HIV. The team expands on well-established ties between the Academic Model for Providing Access to Health Care (AMPATH) and the Veterans Aging Cohort Study (VACS), a longitudinal clinical study of HIV and alcohol. AMPATH treats more than 65,000 HIV patients in 19 clinics in western Kenya. Our goals are to: 1) train Kenyan staff and investigators in research methods and train paraprofessionals in group CBT delivery; 2) pilot the CBT adaptation; and 3) evaluate the feasibility of the paraprofessionally led group CBT via a Stage 1 trial in which 56 HIV infected Kenyans are randomized to same-sex CBT or usual care HIV support groups.

Interventions

BEHAVIORALHIV support group

group support

BEHAVIORALCBT

group cognitive behavioral treatment

Sponsors

Moi Univeristy
CollaboratorOTHER
Indiana University School of Medicine
CollaboratorOTHER
Brown University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* HIV outpatient * hazardous or binge drinker * drank any alcohol in past month * ARV-eligible or initiated on ARVs in past 12 months * within 1 hour travel distance of Eldoret, Kenya HIV clinic * speak Kiswahili

Exclusion criteria

* active psychosis or suicidality * plans to move within next 6 months \> 1 hr travel distance from Eldoret HIV clinic * physically unable to attend sessions * ever attended AMPATH alcohol support group

Design outcomes

Primary

MeasureTime frame
quantity and frequency of alcohol use30 days post-treatment

Countries

Kenya

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026